Sawai Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Second Quarter Ended September 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2019
November 13, 2018
Share
Sawai Pharmaceutical Co., Ltd. reported consolidated earnings results for the second quarter ended September 30, 2018. For the period, the company reported sales were JPY 88,792 million compared to JPY 79,983 million last year. Operating income was JPY 13,766 million compared to JPY 13,435 million last year. Profit before tax was JPY 13,690 million compared to JPY 13,922 million last year. Profit attributable to owners of parent was JPY 10,517 million compared to JPY 10,788 million last year. Diluted earnings per share were JPY 240.10 compared to JPY 292.41 last year.
For the year ending March 31, 2019, the company expects sales will be JPY 172,500 million. Operating profit will be JPY 24,000 million. Profit before tax will be JPY 23,700 million, profit attributable to owners of parent will be JPY 17,400 million and basic earnings per share will be JPY 397.50.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
Sawai Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Second Quarter Ended September 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2019
SAWAI GROUP HOLDINGS CO., LTD. 
